ClinicalTrials.gg
RecruitingNCT07562022Updated Aug 13, 2026

A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma

A Phase 3 interventional study of SCTB35 injection and Rituximab in Follicular Lymphoma (FL), sponsored by Sinocelltech Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-08-13.

Sponsored by Sinocelltech Ltd. (part of Sinocelltech Group Limited) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
93
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 147 studies in Lymphoma, Follicular with a site in China — 75 open to participants now, 88 under way, 20 of them phase 3. Lymphoma, Follicular · China.

Planned enrollment
66th of 132
93 · median 93
Started
2026
with 21 others
Phase 3
28 of 147
13 open now
Primary completion
2028-05
later than 58 of 87 live
Registered
141st of 147
by date

Among the 147 studies in Lymphoma, Follicular with a site in China, this one is the 66th largest by planned enrollment of the 132 interventional ones that give a count, is one of 22 that started in 2026, is one of 28 in phase 3, reaches primary completion later than 58 of the 87 other live ones, and was the 141st registered.

Lymphoma, Follicular

1,891 studies on the registry are indexed under Lymphoma, Follicular; 289 are open to participants now.

Browse Lymphoma, Follicular studies →

Open to participants now

75 of the 147 studies in Lymphoma, Follicular with a site in China are open now. Recruiting first, the newest first:

69 more — sign in →

All 75 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 225 Lymphoma, Follicular studies recruiting now, 158 (70%) set no upper age limit and 39 (17%) stop at 75 or younger; 33 take children under 18; 24 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 147 studies in Lymphoma, Follicular with a site in China, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of SCTB35 in Combination With Lenalidomide in Patients With Relapsed or Refractory Follicular lymphoma (FL).

03

Conditions studied

  • Follicular Lymphoma (FL)
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18-80 years old
  • confirmed Follicular lymphoma (FL) grade 1, 2, or 3a according to WHO 2022 criteria
  • (R/R) disease to at least one prior systemic regimen that contained an anti-CD20 monoclonal antibody (mAb) in combination with chemotherapy
  • Judged by the investigator, the participant must urgently need to receive systemic treatment, based on meeting at least one GELF criterion
  • A measurable or evaluable disease at the time of enrolment
  • PS 0-2
  • Adequate organ function and bone marrow function
  • Expected survival ≥ 6 months

Exclusion criteria

Exclusion Criteria:

  • Documented refractoriness to lenalidomide.
  • Have lenalidomide exposure within 12 months prior to randomization
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
93 participants (estimated)

Study arms

  • Experimental
    SCTB35 and Lenalidomide

    Drug: SCTB35 injection · Drug: Lenalidomide

  • Active comparator
    Rituximab and Lenalidomide

    Drug: Rituximab · Drug: Lenalidomide

Interventions

06

What researchers measure

Primary outcomes

  1. Adverse Events

    Treatment-emergent adverse events/serious adverse events/adverse events of special interest

    Time frame: Up to approximately 3 years

  2. Progression free survival (PFS)

    Defined as the time from the date of randomization to the date of first documentation of progression disease (PD) or the date of death from any cause, whichever occurs first.

    Time frame: Up to approximately 3 years

Secondary outcomes

  1. Percentage of Participants Achieving Best Overall Response (BOR)

    BOR is defined as Complete Response (CR) or Partial Response (PR), determined by Lugano criteria

    Time frame: Up to approximately 3 years

  2. Percentage of Participants Achieving CR

    Percentage of participants who achieve a CR determined per Lugano criteria.

    Time frame: Up to approximately 3 years

  3. Overall Survival (OS)

    Overall survival is defined as the duration from the date of randomization to the date of the participant's death.

    Time frame: Up to approximately 3 years

  4. Duration of Response (DOR)

    DOR is defined as the time from the first occurrence of response (CR or PR) to disease progression or death, whichever occurs first.

    Time frame: Up to approximately 3 years

  5. Time to Response (TTR)

    Time to response is defined for participants achieving a CR/PR as the time from starting therapy to first a CR/PR.

    Time frame: Up to approximately 3 years

  6. Event-Free Survival (EFS)

    EFS is defined as the duration from randomization to disease progression determined by Lugano criteria as assessed by the investigator, initiation of any non-protocol-specified new anti-lymphoma therapy for any reason, or death (whichever occurs first).

    Time frame: Up to approximately 3 years

  7. Duration of Complete Response (DOCR)

    DOCR is defined as the time from the first occurrence of CR to disease progression or death, whichever occurs first.

    Time frame: Up to approximately 3 years

  8. Time to Complete Response (TTCR)

    Time to complete response is defined for participants achieving a CR as the time from starting therapy to first a CR.

    Time frame: Up to approximately 3 years

  9. Blood Concentrations of SCTB35

    The pharmacokinetics of SCTB35 will be analyzed based on the drug concentrations at respective timepoints in the blood samples (or blood derivative)

    Time frame: Up to approximately 1 years

  10. Anti-drug Antibodies of SCTB35

    Blood samples (or blood derivative) will be screened for antibodies binding to SCTB35

    Time frame: Up to approximately 3 years

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for May 2028, 23 months after the start.

Of 45 industry-sponsored phase 3 interventional studies under Lymphoma, Follicular, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 86. This study's planned 23 months is below that.

Counting every sponsor, half of 80 studies reached it within 63 months; a quarter within 36 and three quarters within 106.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 24, 2026
First posted
May 1, 2026
StartActual
Jun 9, 2026
Primary completionEst.
May 2028
CompletionEst.
Jun 2029
Last update
Aug 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07562022
Lead sponsor
Sinocelltech Ltd.
Responsible party
Sponsor
First posted
May 1, 2026
Start date
Jun 9, 2026
Primary completion
May 2028 (estimated)
Completion
Jun 2029 (estimated)
Last update
Aug 13, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: SCTB35

Start the discussion